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Abstract
Background: The diagnosis of childhood tuberculosis remains a challenge worldwide. The Xpert MTB/RIF test, a
rapid mycobacteria tuberculosis diagnostic tool, was recommended for use in children based on data from adult
studies. We evaluated the performance of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary
tuberculosis using one induced sputum sample and described clinical characteristics associated with a positive
Xpert MTB/RIF test. The sputum culture on both Lowenstein-Jensen (LJ) and Mycobacteria Growth Indicator Tube
(MGIT) was the gold standard.
Methods: We consecutively enrolled 250 Ugandan children aged 2 months to 12 years with suspected pulmonary
tuberculosis between January 2011 and January 2012 into a cross-sectional diagnostic study at a tertiary care facility
in Uganda.
Results: We excluded data from 15 children (13 contaminated culture and 2 indeterminate MTB/RIF test results)
and analysed 235 records. The Xpert MTB/RIF test had a sensitivity of 79.4% (95% CI 63.2 - 89.7) and a specificity of
96.5% (95% CI 93 – 98.3). The Xpert MTB/RIF test identified 13 of the 14 (92.9%) smear positive-culture positive and
14 of the 20 (70%) smear negative -culture positive cases. The Xpert MTB/RIF identified twice as many cases as the
smear microscopy (79.4% Vs 41.2%). Age > 5 years (OR 3.3, 95% CI 1.4 – 7.4, p value 0.005), a history of Tuberculosis
(TB) contact (OR 2.4, 95% CI 1.1 – 5.2, p value 0.03), and a positive tuberculin skin test (OR 4.1, 95% CI 1.7 – 10,
p value 0.02) was associated with a positive Xpert MTB/RIF test. The median time to TB detection was 49.5 days
(IQR 38.4-61.2) for LJ, and 6 days (IQR 5 – 11.5) for MGIT culture and 2 hours for the Xpert MTB/RIF test.
Conclusion: The Xpert MTB/RIF test on one sputum sample rapidly and correctly identified the majority of children
with culture confirmed pulmonary tuberculosis with high specificity.
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Background
Diagnosis of childhood pulmonary tuberculosis (PTB)
has inherent challenges such as the paucibacillary nature
of the disease, difficulties in obtaining sufficient sputum
samples, intrinsic limitations of available tests, and o-
verlap of respiratory clinical presentation in Human
Immune Deficiency Virus (HIV) infection [1-3]. The
current methods used in the diagnosis of tuberculosis
(TB) have not greatly impacted on the diagnostic process
in the paediatric population and this has resulted into
delayed diagnosis or misdiagnosis and subsequent over
or under treatment [1,3,4]. Even though sputum culture
is considered the gold standard diagnostic tool for PTB,
it is only able to detect approximately 30 – 40% of cases
with probable tuberculosis in children [4-6]. While
smear microscopy is inexpensive, simple to perform, and
has a quick turnaround time, the proportion of positive
samples among children is minimal due to the low bacil-
lary burden observed in childhood tuberculosis [4].
Newer tools such as the Nucleic Acid Amplification
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Tests have a slightly higher sensitivity of 40 – 60% [4].
Other diagnostic tests including the Tuberculin Skin
Test (TST) and the Interferon γ Release Assays are limi-
ted in differentiating between latent infection and active
disease [4]. When compared to adults, children have a
higher risk of severe progressive disease and death due
to tuberculosis hence the urgent need for a rapid and ac-
curate diagnostic tool [2].
The recent innovation of the Xpert MTB/RIF test by
Cepheid, Sunnyvale, CA (USA) has greatly transformed the
field of TB diagnostics [7]. The Xpert MTB/RIF test simul-
taneously detects mycobacteria tuberculosis (MTB) and
resistance to rifampicin using real-time polymerase chain
reaction (PCR) analysis and avails results within 2 hours
[7]. The other main advantage of the XpertMTB/RIF com-
pared to the traditional PCR methods is the possibility to
use it in a relatively peripheral laboratory setting because it
is fully automated.
In the policy statement on the Xpert MTB/RIF test in
2011, the World Health Organisation (WHO) recom-
mended the use of the test as an initial diagnostic tool
among children with suspected HIV associated TB or
Multi-Drug Resistant TB based on successful data
among adults [8-10]. Boehme et al. documented sensiti-
vity of 98.2% and 72.5% among adults with culture
positive-smear positive and culture positive–negative
culture positive tuberculosis respectively in a multicenter
study conducted in Peru, Azerbaijan, South Africa, and
India [9]. There are limited published data on the utility
of the Xpert MTB/RIF test in the paediatric population
with tuberculosis [11,12]. A recent study by Nicol MP
et al. found an overall sensitivity of 100% for smear
positive-culture positive cases, 61.1% for smear negative-
culture positive, and specificity of 98.8% when two in-
duced sputum samples was assessed among children
aged less than 15 years with suspected pulmonary tuber-
culosis in Cape Town, South Africa [11]. Similar findings
were reported by Rachow et al. in a prospective study
conducted in Tanzania where the Xpert MTB/RIF test
detected 100% of smear positive-culture positive cases
and 66.6% for smear negative-culture positive cases [12].
We therefore aimed to evaluate the performance of the
Xpert MTB/RIF test for the diagnosis of childhood pul-
monary tuberculosis in Uganda and describe clinical
characteristics associated with a positive Xpert MTB/RIF
test using one induced sputum sample and sputum cul-
ture on both Lowenstein-Jensen (LJ) and Mycobacteria
Growth Indicator Tube (MGIT) as the gold standard.
Methods
Study participants
We conducted a cross-sectional diagnostic study at the
Mulago National Referral Hospital in Kampala, Uganda
on both paediatric in-patients and out-patients aged
2 months to 12 years with suspected pulmonary tubercu-
losis between January 2011 and January 2012. Eligibility
for enrolment was based on the WHO case definition for
a TB suspect [13,14] and included having a persistent
cough of 2 weeks or more and one of the following:
household TB contact, unexplained weight loss or failure
to gain weight, and unexplained fever for 2 weeks or more.
We excluded children who were on anti- tuberculous
therapy and those in whom sputum could not be obtained
or sputum induction was contraindicated. The contraindi-
cations to sputum induction were adapted from the WHO
guidelines for sputum induction and included: severe re-
spiratory distress (including rapid breathing, wheezing,
hypoxia); intubated patient; bleeding: low platelet count,
bleeding tendency, severe nosebleeds (symptomatic or
platelet count <50/ml blood); reduced level of conscious-
ness and history of significant asthma (diagnosed and
treated by a clinician) [13]. The exclusion criterion “chil-
dren in whom sputum could not be obtained” was defined
after systematic attempt of sputum induction.
Study procedure
The study was approved by the School of Medicine
Research and Ethics committee of Makerere University
College of Health Sciences (# REC REF 2011–005). The
children were enrolled upon provision of informed con-
sent from the primary caregivers and assent for those
older than 8 years. We conducted consecutive enrolment
until the desired sample size was achieved. Upon enrol-
ment, a clinical history and physical examination were
conducted. The investigations performed included the
TST, Complete Blood Count, HIV testing in children
whose HIV status was unknown, and chest radiography.
Each child’s nutritional status was assessed using the
WHO child growth standards [15]. Weight for length/
weight for height was used for children < 5 years while
Body Mass Index (BMI) for Age was used for children ≥
5 years. Severe wasting was defined as weight for length
or weight for height or BMI for age Z score which was
less than – 3SD.
Chest radiography
The chest radiographs (Antero-Posterior views) were
evaluated for pulmonary tuberculosis by two independ-
ent reviewers who used a standardised reporting form
and were blinded to the results of the other investiga-
tions. A third independent reviewer evaluated a radio-
graph in the event that there was discordant reporting
between the two reviewers. The reviewers classified the
chest radiographs into probable TB (findings consistent
with TB), possible TB (atypical findings), and TB unlikely
(findings not consistent with TB or normal chest radio-
graph) based on the radiological features present [16].
Findings consistent with TB included lymphadenopathy
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for children 5 years and below while, a typical adult type
of chest radiograph appearance with predominance of
upper lobe infiltrates with or without cavitation was
used for older children. A miliary pattern was catego-
rized as probable TB.
Tuberculin skin test
A qualified trained study nurse administered 0.1 ml of
purified protein derivative (PPD; 2TU, PPD RT23, Staten
Serum Institute, Denmark, Copenhagen) intradermally
on the volar aspect of the less dominant forearm. The
induration at the site of administration was measured in
millimetres after 48–72 hours of administration. A po-
sitive skin test was defined as > 5 mm of the transverse
induration in children with HIV infection and > 10 mm
in children without HIV infection.
Sputum sample collection
A qualified trained study nurse performed sputum in-
duction using nebulised 3% hypertonic saline after a
minimum of 3 hours fast. The study participants under-
went premedication with nebulised salbutamol prior to
the administration of nebulised 3% hypertonic saline. A
maximum of two attempts were conducted to obtain an
adequate sample of at least 3 mls of sputum. However
whatever volume of samples obtained was sent for ana-
lysis. The study participants had pulse oximetry moni-
toring during and for one hour after the procedure. The
sputum sample was collected in a sterile container which
was placed on an ice pack in a cool box, taken to an
accredited mycobacteriology laboratory (Makerere Uni-
versity Department of Microbiology – Mycobacteriology
Laboratory) and processed within two hours of collec-
tion. Digestion-Decontamination of sputum by N- acetyl
L- cysteine (NALC)-Sodium Hydroxide method was
performed prior to making smears for fluorochrome
staining with Auramine O Phenol and examined
according to standards. Samples were inoculated into
the Mycobacteria Growth Indicator Tube (MGIT)
(Becton Dickson, Franklin Lakes, NJ) and Lowenstein-
Jensen (LJ) slants and incubated for 6 weeks on MGIT
and 8 weeks on LJ culture. At least 0.5 ml of the sedi-
ment sample was stored at – 20°C for the Xpert MTB/
RIF test. Due to the delay in delivery of the Xpert MTB/
RIF cartridges and sample reagents, we were unable to
run the Xpert MTB/RIF test on the freshly collected
sputum samples. A culture was considered positive if
mycobacterium tuberculosis growth was confirmed on
either LJ or MGIT media. A culture was considered
negative if no growth was confirmed on both LJ and
MGIT media, if one culture result was negative and the
other was contaminated. A culture was considered con-
taminated if both LJ and MGIT demonstrated contamin-
ation. Mycobacteria Other Than Tuberculosis (MOTT)
was considered if both LJ and MGIT culture media grew
MOTT. Mycobacterial identification was done using
Capilia TB Neo™ (TAUN, Numazu, Japan) assay. The
frozen samples were thawed to room temperature prior
to addition of the Xpert MTB/RIF sample reagent. Three
parts (1.5 ml) of the sample reagent were added to one
part (0.5 ml) of the sediment sample as per the manufac-
turer’s guide. The mixture was shaken and incubated at
room temperature for 15 minutes. The mixture was then
transferred to a pre labeled cartridge and subsequently
loaded into the Xpert MTB/RIF machine. The results
were printed out after a 2 hours cycle was complete. An
Xpert MTB/RIF test was considered positive if MTB was
detected and negative if MTB was not detected. We
were unable to run a repeat test for the indeterminate
MTB/RIF test result as the stored sputum sample was
insufficient. Drug susceptibility testing was not per-
formed in children identified with rifampicin resistance
based on Xpert test due to cost limitations. The indeter-
minate test results were reported as such and were
excluded from analysis. Quality control measures for the
Xpert MTB/RIF test included negative and positive con-
trol tests for every new batch of Xpert MTB/RIF car-
tridges; monthly negative and positive control tests;
monthly room swabs for mycobacteria tuberculosis con-
tamination; and automated quality control for PCR. The
laboratory technologists processing the sputum samples
for culture and Xpert MTB/RIF were blinded to the
results of the other test.
Blood sample collection
Using aseptic technique, 3mls of venous blood were
drawn for CBC and HIV testing under aseptic condi-
tions. The CBC assays were performed using Beckman
Dickinson Coulter Counter (5 Part-Differential). HIV
rapid testing was conducted on all children without a
documented HIV status. HIV exposed infants aged
18 months or younger had an HIV DNA PCR done to
confirm the diagnosis. The HIV rapid test algorithm




At the time we started data collection, there were no
published data on evaluation of the Xpert MTB/RIF
among children. Sensitivity and specificity normograms
with a fixed false positive rate of 5% were used to calcu-
late the sample size for this study [17]. Using a preva-
lence of culture confirmed pulmonary tuberculosis of
30% in a Ugandan paediatric population,[5] sensitivity of
the Xpert MTB/RIF test in the adult population of 98.2%
[9] and 95% confidence interval, we obtained a sample
size 250 study participants.
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Data analysis
The data were captured using EPI INFO version 3.5.3,
analysed using STATA version 10 and OpenEpi. We
described data for all enrolled study participants but
excluded data of children with indeterminate MTB/RIF
test results and contaminated sputum cultures from the
diagnostic accuracy analysis. Study population characte-
ristics were described using proportions with 95% CI,
means with standard deviations, and medians with inter-
quartile ranges (IQR). We excluded data of children with
indeterminate MTB/RIF test results and contaminated
sputum culture results from the diagnostic accuracy ana-
lysis. Sensitivity, specificity, positive and negative pre-
dictive values, positive and negative likelihood ratios
with their 95% CI for the Xpert MTB/RIF test were cal-
culated using sputum culture as the gold standard. The
chi square statistical test was used to compare the pro-
portions. We explored the clinical characteristics asso-
ciated with a positive Xpert MTB/RIF test result using
multivariate logistic regression analysis. The clinical cha-
racteristics with a p value of < 0.2 on bivariate analysis
and those associated with PTB were entered into the
logistic regression model using the backward stepwise




We enrolled 255 (92.7%) of 275 eligible study participants
and described data for 250 study participants. (See Figure 1)
All the 250 study participants had sputum cultures (both
LJ and MGIT) and Xpert MTB/RIF tests conducted. The
median age was 36 months (IQR 16 – 74.5) and 41.6%
were HIV positive. The study participant characteristics are
as shown in Table 1.
Fifteen children (6%, 95% CI 3.4- 9.7) had a positive
sputum smear for acid fast bacilli. There were thirty five
Evaluated (n=250)
Enrolled (n = 255)
Excluded from analysis (n=5) 
Unable to obtain a sputum sample
after induction
Excluded (n=20)
Declined consent - 10
On TB therapy - 10
Screened (n = 385)
Eligible (n = 275)
Not Eligible (n = 110)
































Figure 1 Study profile.
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children (14%, 95% CI 9.9 – 18.9) with a positive sputum
culture for MTB and thirty five children (14%, 95% CI
9.9 – 18.9) with a positive Xpert MTB/RIF test. Two
(5.7% 95% CI 0.6 – 19.1) of the 35 children with a posi-
tive MTB/RIF test had rifampicin resistance detected.
We documented a positive Xpert MTB/RIF test in 14 of
the 15 (93.3%, 95% CI 68.1 - 99.8) positive smears.
Twelve (34.3%) of the children with a positive sputum
culture were HIV positive while thirteen children
(37.1%) with a positive Xpert MTB/RIF test were HIV
positive. There was no statistically significant difference
in the positivity rate for the Xpert MTB/RIF results
between HIV positive and negative children. We docu-
mented a positive Xpert MTB/RIF test in 9.5% (4 of 42),
9.9% (13 of 131), and 23.4% (18 of 77) of children aged
< 1 year, 1 – 5 years, and > 5 years respectively. Three
children (3/35, 8.6%) had MTB growth on LJ media and
MOTT on MGIT media. Two of the three children had
a positive Xpert MTB/RIF test.
Thirteen sputum cultures (5.2%, 95% CI 2.8 – 8.7%)
were classified as contaminated while 2 Xpert MTB/RIF
test results (0.8%, 95% CI 0.1 – 2.9) were indeterminate.
While the median time to detection was 49.5 days (IQR
38.4-61.2) for LJ and 6 days (IQR 5 – 11.5) for MGIT
culture, it was 2 hours for the Xpert MTB/RIF test.
Chest radiographs for 235 study participants were
reviewed and classified as probable TB (80/235, 34%
(95% CI 28–40.5)); possible TB (96/235, 40.9% (95% CI
34.5-47.4)), and TB unlikely (46/235, 19.6% (95% CI
14.7-25.2)). Thirteen of 235 (5.5%, 95% CI 3–9.3) radio-
graph reviews were inconclusive in that all the three re-
viewers did not agree. Fifteen chest radiographs were
not reviewed as these children were lost to follow up be-
fore the radiographs were taken.
Diagnostic test results
For diagnostic accuracy, we excluded data from 15 chil-
dren (13 contaminated culture and 2 indeterminate
MTB/RIF test results) and analysed 235 records. The
Xpert MTB/RIF test identified MTB in 27 of the 34 cul-
ture confirmed cases demonstrating a sensitivity of
79.4% (95% CI 63.2 – 89.7) and 7 of 201 culture negative
cases, a specificity of 96.5% (95% CI 93 – 98.3). More
diagnostic parameters are shown in Table 2. Fourteen of
the 34 culture positives were smear positive (41.2%, 95%
CI 24.6 – 59.3). The Xpert MTB/RIF test identified twice
as many cases as the smear microscopy (79.4% Vs
41.2%). The Xpert MTB/RIF test identified 13 of 14
smear positive-culture positive (93%, 95% CI 66–99.8)
and 14 of 20 smear negative -culture positive cases (70%,
Table 1 Characteristics of study participants with
suspected pulmonary tuberculosis (N = 250)
Characteristic Frequency Percentage
Age < 1 year 42 16.8
1-5 years 131 52.4
> 5 years 77 30.8
Sex Male 134 53.6
Female 116 46.4
Patient status Inpatient 211 84.4
Outpatient 39 15.6
HIV status Positive 104 41.6
Negative 146 58.4
History of TB contact Yes 86 34.4
No 164 65.6






History of INH prophylaxis Yes 1 0.4
No 249 99.6
Tuberculin skin test Positive 76 30.4
Negative 174 69.6
Severe wasting* Yes 68 27.2
No 182 72.8
BCG scar Yes 169 67.6
No 81 32.4
* Weight for height/length < 5 years, BMI/Age ≥ 5 years which was < −3SD.
Table 2 The Xpert MTB/RIF test evaluation among children with suspected pulmonary TB (N = 235)
Overall (n = 235) HIV positive (n = 99) HIV negative (n = 136)
Estimate 95% CI Estimate 95% CI Estimate 95% CI
Sensitivity (%) 27/34, 79.4 63.2 - 89.7 9/11,81.8 52.3-94.9 18/23, 78.3 58.1-90.3
Specificity (%) 194/201, 96.5 93- 98.3 84/88,95.5 88.9- 98.2 110/113, 97.4 92.5- 99.1
PPV (%) 79.4 63.2- 89.7 69.2 42.4- 87.3 85.7 65.4- 95
NPV (%) 96.2 93-98.3 97.7 91.9-99.4 95.7 90.2- 98.1
Diagnostic accuracy (%) 94 90.3- 96.4 93.9 87.4-97.2 94.1 88.8- 97
Likelihood ratio (+) 22.8 16.9 - 30.7 18 10.5 - 30.8 29.5 14.9- 58.4
Likelihood ratio (−) 0.2 0.2- 0.3 0.2 0.1-0.5 0.2 0.2 - 0.3
PPV – Positive Predictive Value; NPV – Negative Predictive Value.
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95% CI 46–88). Twenty one of 221 (9.5%, 95% CI
6 – 14.2) negative smears were Xpert MTB/RIF positive.
The Xpert MTB/RIF test had a sensitivity of 93.3% (95%
CI 70.2 – 98.8) and specificity of 94.8% (95% CI 85.9 –
98.2) among children aged 5 years and above. The sensi-
tivity and specificity of the Xpert MTB/RIF test was
68.2% (95% CI 46 – 84.6) and 97.2% (95% CI 93 – 98.9)
respectively among children aged 5 years and below.
The clinical characteristics which were independently as-
sociated with a positive Xpert MTB/RIF test included
age > 5 years, a positive history of TB contact, and a
positive tuberculin test (Table 3).
Discussion
In the policy statement on the Xpert MTB/RIF test in
2011, the WHO recommended the use of the test as an
initial diagnostic tool among children with suspected
HIV associated TB or MDR TB based on significant data
among adults [8].
The proportion of children (14%) with a positive Xpert
MTB/RIF was similar to that reported (13%) from a lar-
ger and younger paediatric South African population in
a high TB/HIV prevalent area [11]. The Xpert MTB/RIF
test correctly identified 79.4% and 96.5% of children with
and without culture confirmed pulmonary tuberculosis
respectively. Using the Fagan normogram, at a childhood
PTB prevalence of 14% from our study and an overall
positive likelihood ratio of 23, the probability of pul-
monary tuberculosis when the Xpert MTB/RIF test is
positive is 80% while the probability of pulmonary tuber-
culosis when the Xpert MTB/RIF test is negative is 3%
[18]. This gives the clinician sufficient confidence to
make a diagnosis of pulmonary tuberculosis when the
Xpert MTB/RIF test is positive. A negative Xpert MTB/
RIF test does not exclude a diagnosis of pulmonary
tuberculosis given the fact that the test was unable to
identify 20.6% of children with culture confirmed pul-
monary tuberculosis. A clinical decision in the context
of the patient is therefore important in initiating anti-
tuberculous therapy in a child who has a negative Xpert
MTB/RIF test. Just as in the South African and Mbeya
studies, our results demonstrate that the Xpert MTB/
RIF test identified majority of the culture confirmed
cases with high specificity [11,12]. While we did not per-
form a second Xpert MTB/RIF test, our results are
highly comparable to the studies conducted in high TB
prevalent areas in South Africa and Mbeya where mul-
tiple sputum samples were used [11,12]. We do not dis-
courage the use of a second Xpert MTB/RIF test but the
decision needs to be guided by the available resources.
We also documented a lower sensitivity (70%) among
smear negative-culture positive case and twice as many
cases with the Xpert MTB/RIF test as did smear micros-
copy. The documentation of twice as many cases with
the Xpert MTB/RIF test as with smear microscopy also
underscores the clinical relevance of the Xpert MTB/RIF
test. Studies conducted in the adult population have
reported slightly higher sensitivity values of nearly 73%
among smear negative culture positive cases [9,10]. The
differences between adults and children could be related
to the inherent low sensitivity of the culture method,
higher AFB load in adults, and the occurrence of smear
negative primary disease among children.
Although the Xpert MTB/RIF test was unable to iden-
tify nearly 21% of the culture positive cases, the median
time to TB detection was significantly shorter than that
for LJ and MGIT culture methods. The Xpert MTB/RIF
test also presents a hands-free sample processing tech-
nique which can be operated by an individual with min-
imal training [7]. This greatly impacts on the time taken
to process a sputum sample for smear microscopy and
culture as well as limit a laboratory technician’s exposure
to MTB. We documented higher contamination rates
with the culture method compared to the indeterminate
results observed with the Xpert MTB/RIF test. A feasi-
bility and effectiveness study conducted among adults
with suspected tuberculosis or multidrug-resistant tu-
berculosis at the District and Sub District health cen-
ters in TB endemic resource limited areas reported that
the Xpert MTB/RIF test is effective in reducing the
time to initiation of anti-tuberculous therapy as well as
lost to follow up cases due to delays in making a diag-
nosis [19]. The Xpert MTB/RIF test may be more ex-
pensive than smear microscopy but the costs are
Table 3 Clinical characteristics associated with a positive xpert MTB/RIF test (N = 235)
Variable Crude OR (95% CI) P value Adjusted OR (95% CI) P value
Age (> 5 years Vs ≤ 5 years) 2.6 (1.2 -5.4) 0.012 3.3 (1.4 - 7.4) 0.005
Sex (female vs. male) 1.1 (0.5 – 2.2) 0.9
Positive HIV status 0.8 (0.4 - 1.7) 0.6 1.2 (0.5 – 3.0) 0.7
Positive history of TB contact 2.8 (1.4 - 5.9) 0.006 2.4 (1.1 – 5.2) 0.03
Prior TB diagnosis 0.8 (0.2 - 3.8) 0.8
Positive TST 3.4 (1.6 - 7.3) 0.001 4.1 (1.7 - 10) 0.002
BCG scar present 0.7 (0.3 - 1.5) 0.4
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similar to running sputum culture and drug susceptibil-
ity testing [19].
Unlike the South African study, both the Mulago and
Mbeya studies found no statistical difference in the
Xpert MTB/RIF positivity rate between HIV positive and
negative children There was a larger proportion of HIV
infected children in the Mulago (40.9%) and Mbeya
(58.9%) studies when compared to the South African
study (24%) [11,12]. Also, children with HIV commonly
present with respiratory complications that may mimic
pulmonary TB [2].
Due to the limited availability of the Xpert MTB/RIF
test, we explored the clinical characteristics associated
with a positive Xpert MTB/RIF test in order to help cli-
nicians predict which child is likely to have a positive
test. We found that age > 5 years, a positive TST, and a
positive history of TB contact were independently asso-
ciated with a positive Xpert MTB/RIF test. Unlike youn-
ger children who get paucibacillary primary disease,
older children especially those above 10 years of age are
more likely to get reactivation/cavitatory disease there
by increasing the likelihood of a positive Xpert MTB/
RIF test [20]. A history of TB exposure increases the
likelihood of occurrence of TB in a child with suspected
pulmonary tuberculosis. A positive TST response is a
marker of TB exposure and also increases the likelihood
of occurrence of TB in a child with suspected pulmonary
tuberculosis. The other studies have mainly been des-
criptive and have not looked at factors associated with a
positive Xpert MTB/RIF test.
We documented three children who had both MTB
and MOTT LJ and MGIT media. Of these, two had a
positive Xpert MTB/RIF test. This suggests the possi-
bility for co infection with both MTB and MOTT. We
reported two children with rifampicin resistance among
those with a positive Xpert MTB/RIF test. It is possible
that the resistance was secondary as opposed to primary
because the two children had defaulted several times
due to medication shortages. These children were re-
ferred to the National TB and Leprosy Program for fur-
ther management and follow-up. Since we did not
perform drug susceptibility testing, we were unable to
comment on the performance of the Xpert MTB/RIF
test in identifying rifampicin resistance.
This is the first study in Uganda and one of the very
few large studies worldwide that have evaluated the per-
formance of the Xpert MTB/RIF test in the diagnosis of
pulmonary tuberculosis among children. We also ex-
plored the factors associated with a positive Xpert test
which had not been described in earlier studies. The fact
that all study participants were hospital cases might
affect the generalisability of these study findings to the
community setting. The low sensitivity of sputum cul-
ture for PTB in children makes it an inadequate
diagnostic tool to compare with especially when more
sensitive tools are being assessed. Due to the small
amounts of the sputum sample stored, we were unable
to run a repeat Xpert MTB/RIF test in cases where the
initial test was indeterminate. Even though we per-
formed the Xpert MTB/RIF test on frozen samples, an
earlier study by Theron G et al. demonstrated no signifi-
cant difference in sensitivity when the sputum samples
were frozen [21].
Even though an earlier study conducted among adults
demonstrated similar performance of the Xpert MTB/
RIF test for untreated and treated sputum, [9] we re-
commend a similar study in the pediatric population
which is faced with paucibacillary primary disease and
difficulties in obtaining adequate sputum samples. We
also suggest a study to assess the performance of the
Xpert MTB/RIF test at the District and Sub-District
levels as the population at a national referral hospital
differs from that at the lower health facilities. A study at
the lower health facilities will also assess the feasibility
of performing sputum induction at these facilities.
Uganda as a developing country is faced with challenges
including costs of purchase and maintenance, infrastruc-
ture at the lower health facilities, and power shortages,
thereby hindering the sustainability of this service. The
WHO has however revised the purchase costs to cater
for resource poor countries including Uganda. Also, ef-
forts to improve on the diagnosis of pediatric TB can be
used as a platform to argue for better government sup-
port and commitment in managing TB among children.
Conclusions
The Xpert MTB/RIF test on one sputum sample rapidly
and correctly identified the majority of children with
culture confirmed pulmonary tuberculosis with high
specificity. Age > 5 years, a positive TST, and a positive
history of TB contact were positively associated with a
positive Xpert MTB/RIF test.
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